- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940205
Machine-learning Algorithm for Prediction of CKD From Retinal Images (healthy route)
A Validation Study to Assess Performance Accuracy of a Machine-Learning Algorithm for the Prediction of Chronic Kidney Disease (CKD) From Digital Retinal Images
This is a non-interventional study being conducted to validate the performance of a machine learning algorithm for prediction of eGFR from digital retinal images in a target population for future intended use as a populated-based screening tool. Secondary objectives will include prediction of blood pressure (> or ≤ 140/90 mmHg) and presence or absence of T2DM as determined by glycated haemoglobin (HbA1c >6.5%) or on the basis of clinical history. Once validated, the methodology will be deployed for health screening to improve access to healthcare.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mohamed Khalis, Professor
- Numéro de téléphone: +212 628-245023
- E-mail: mkhalis@um6ss.ma
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population consists of adult patients diagnosed with chronic kidney disease (CKD), hypertension, diabetes mellitus, or without these conditions, attending routine outpatient clinics at Hôpital Universitaire International Cheikh Khalifa Ibn Zaid in Casablanca and Centre Hospitalier Universitaire Hassan II in Fez, Morocco.
La description
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
- Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Previously documented eGFR ≥ 3months
- Any participant with a positive dipstick result for proteinuria of at least trace
- Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
Exclusion Criteria:
-
Participants are excluded from the study if any of the following criteria apply:
- As judged by the investigator, any evidence of a condition which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Any known eye condition that may preclude clear imaging of the retina for example; cataracts
- Individuals with hypertensive emergencies and hyperglycemic or hypoglycemic emergencies
- Involvement in the planning and/or conduct of the study (applies to HHA/ AstraZeneca staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: CROSS_SECTIONAL
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
CKD Cases
350 participants (cases) with diabetes and/or hypertension and/or CKD with previously documented eGFR < 60 ml/min/1.73m2 ≥3 months |
A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease |
|
Controls
150 (controls) with previously documented eGFR ≥ 60 ml/min/1.73m2 ≥ 3 months |
A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The accuracy of a machine-learning based algorithm to predict high risk CKD from digital retinal images
Délai: Baseline
|
To quantify the discrimination of the machine-learning algorithm for identifying the binary target condition of persistent eGFR <60 mL/min/1.73 m², using standard-of-care serum creatinine as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure |
Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Accuracy of the Machine Learning Algorithm for Detection of Hypertension and T2DM
Délai: Baseline
|
To quantify the sensitivity, specificity, and discriminative performance of a machine-learning-based algorithm for identifying SBP >140 mmHg from digital retinal images, using standard-of-care assessment as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure |
Baseline
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies du système endocrinien
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Maladies métaboliques
- Troubles du métabolisme du glucose
- Diabète sucré
- Insuffisance rénale
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Hypertension
- Diabète sucré, Type 2
- Insuffisance rénale chronique
Autres numéros d'identification d'étude
- CKD-AI-2026-07
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .